# One Stop Systems, Inc.: financial statements, quarterly OSS · Nasdaq · CIK 1394056 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/oss.md) · [Financials](/companies/oss/financials.md) · [Filings](/companies/oss/filings.md) · [Insiders](/companies/oss/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/oss/financials.md?period=annual). ## Income statement | Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [13.2 d](/filings/0000950170-25-041974.md) | [12.7](/filings/0000950170-25-065032.md) | [13.2](/filings/0000950170-25-104624.md) | [13.7](/filings/0001193125-25-265826.md) | [(15.0) d](/filings/0001193125-26-114051.md) | [5.2](/filings/0001193125-26-207665.md) | [5.8](/filings/0001193125-26-333905.md) | [9.3](/filings/0001193125-26-435152.md) | [12.0 d](/filings/0001193125-26-114051.md) | [8.1](/filings/0001193125-26-207665.md) | [9.3](/filings/0001193125-26-333905.md) | [12.6](/filings/0001193125-26-435152.md) | | Cost of revenue | $m | [8.7 d](/filings/0000950170-25-041974.md) | [8.9](/filings/0000950170-25-065032.md) | [9.9](/filings/0000950170-25-104624.md) | [15.4](/filings/0001193125-25-265826.md) | [(10.3) d](/filings/0001193125-26-114051.md) | [2.8](/filings/0001193125-26-207665.md) | [3.4](/filings/0001193125-26-333905.md) | [5.0](/filings/0001193125-26-435152.md) | [5.0 d](/filings/0001193125-26-114051.md) | [3.9](/filings/0001193125-26-207665.md) | [5.7](/filings/0001193125-26-333905.md) | [7.2](/filings/0001193125-26-435152.md) | | Gross profit | $m | [4.4 d](/filings/0000950170-25-041974.md) | [3.7](/filings/0000950170-25-065032.md) | [3.3](/filings/0000950170-25-104624.md) | [(1.7)](/filings/0001193125-25-265826.md) | [(4.7) d](/filings/0001193125-26-114051.md) | [2.4](/filings/0001193125-26-207665.md) | [2.4](/filings/0001193125-26-333905.md) | [4.2](/filings/0001193125-26-435152.md) | [7.0 d](/filings/0001193125-26-114051.md) | [4.2](/filings/0001193125-26-207665.md) | [3.7](/filings/0001193125-26-333905.md) | [5.4](/filings/0001193125-26-435152.md) | | Research and development | $m | [1.1 d](/filings/0000950170-25-041974.md) | [1.0](/filings/0000950170-25-065032.md) | [0.9](/filings/0000950170-25-104624.md) | [1.0](/filings/0001193125-25-265826.md) | [0.6 d](/filings/0001193125-26-114051.md) | [1.2](/filings/0001193125-26-207665.md) | [1.4](/filings/0001193125-26-333905.md) | [1.3](/filings/0001193125-26-435152.md) | [1.6 d](/filings/0001193125-26-114051.md) | [0.8](/filings/0001193125-26-207665.md) | [0.9](/filings/0001193125-26-333905.md) | [1.1](/filings/0001193125-26-435152.md) | | Selling, general and administrative | $m | [2.0 d](/filings/0000950170-25-041974.md) | [2.1](/filings/0000950170-25-065032.md) | [2.4](/filings/0000950170-25-104624.md) | [2.1](/filings/0001193125-25-265826.md) | [0.6 d](/filings/0001193125-26-114051.md) | [1.9](/filings/0001193125-26-207665.md) | [1.9](/filings/0001193125-26-333905.md) | [1.7](/filings/0001193125-26-435152.md) | [1.8 d](/filings/0001193125-26-114051.md) | [2.4](/filings/0001193125-26-207665.md) | [2.5](/filings/0001193125-26-333905.md) | [3.2](/filings/0001193125-26-435152.md) | | Operating income | $m | [(0.3) d](/filings/0000950170-25-041974.md) | [(1.3)](/filings/0000950170-25-065032.md) | [(2.3)](/filings/0000950170-25-104624.md) | [(6.7)](/filings/0001193125-25-265826.md) | [(5.4) d](/filings/0001193125-26-114051.md) | [(2.4)](/filings/0001193125-26-207665.md) | [(2.5)](/filings/0001193125-26-333905.md) | [(0.4)](/filings/0001193125-26-435152.md) | [1.9 d](/filings/0001193125-26-114051.md) | [(0.7)](/filings/0001193125-26-207665.md) | [(7.7)](/filings/0001193125-26-333905.md) | [(0.8)](/filings/0001193125-26-435152.md) | | Interest expense | $m | [0.0 d](/filings/0000950170-25-041974.md) | [0.0](/filings/0000950170-25-065032.md) | [0.0](/filings/0000950170-25-104624.md) | [0.0](/filings/0001193125-25-265826.md) | [(0.1) d](/filings/0001193125-26-114051.md) | [0.0](/filings/0000950170-25-065032.md) | [0.0](/filings/0000950170-25-104624.md) | [0.0](/filings/0001193125-25-265826.md) | [(0.0) d](/filings/0001193125-26-114051.md) | not reported | not reported | not reported | | Income tax | $m | [0.0 d](/filings/0000950170-25-041974.md) | [0.2](/filings/0000950170-25-065032.md) | [0.2](/filings/0000950170-25-104624.md) | [0.2](/filings/0001193125-25-265826.md) | [(0.6) d](/filings/0001193125-26-114051.md) | [0.1](/filings/0000950170-25-065032.md) | [0.2](/filings/0000950170-25-104624.md) | [0.3](/filings/0001193125-25-265826.md) | [(0.6) d](/filings/0001193125-26-114051.md) | not reported | not reported | not reported | | Net income | $m | [(0.3) d](/filings/0000950170-25-041974.md) | [(1.3)](/filings/0000950170-25-104624.md) | [(2.3)](/filings/0000950170-25-104624.md) | [(6.8)](/filings/0001193125-25-265826.md) | [(3.1) d](/filings/0001193125-26-114051.md) | [(2.0)](/filings/0001193125-26-333905.md) | [(2.0)](/filings/0001193125-26-333905.md) | [0.3](/filings/0001193125-26-435152.md) | [8.9 d](/filings/0001193125-26-114051.md) | [(0.5)](/filings/0001193125-26-333905.md) | [(7.3)](/filings/0001193125-26-333905.md) | [(0.6)](/filings/0001193125-26-435152.md) | | Diluted EPS | $ per share | not reported | [(0.06)](/filings/0000950170-25-065032.md) | [(0.11)](/filings/0000950170-25-104624.md) | [(0.32)](/filings/0001193125-25-265826.md) | not reported | [(0.09)](/filings/0001193125-26-333905.md) | [(0.09)](/filings/0001193125-26-333905.md) | [0.01](/filings/0001193125-26-435152.md) | not reported | [(0.02)](/filings/0001193125-26-207665.md) | [(0.29)](/filings/0001193125-26-333905.md) | [(0.02)](/filings/0001193125-26-435152.md) | | Basic EPS | $ per share | not reported | [(0.06)](/filings/0000950170-25-065032.md) | [(0.11)](/filings/0000950170-25-104624.md) | [(0.32)](/filings/0001193125-25-265826.md) | not reported | [(0.09)](/filings/0001193125-26-207665.md) | [(0.09)](/filings/0001193125-26-333905.md) | [0.01](/filings/0001193125-26-435152.md) | not reported | [(0.02)](/filings/0001193125-26-207665.md) | [(0.29)](/filings/0001193125-26-333905.md) | [(0.02)](/filings/0001193125-26-435152.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfRevenue - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [4.0](/filings/0000950170-25-041974.md) | [6.9](/filings/0000950170-24-056865.md) | [6.8](/filings/0000950170-24-093868.md) | [9.4](/filings/0000950170-24-121839.md) | [4.0](/filings/0001193125-26-114051.md) | [6.5](/filings/0000950170-25-065032.md) | [8.5](/filings/0000950170-25-104624.md) | [6.5](/filings/0001193125-25-265826.md) | [31.2](/filings/0001193125-26-435152.md) | [24.3](/filings/0001193125-26-207665.md) | [17.3](/filings/0001193125-26-333905.md) | [5.6](/filings/0001193125-26-435152.md) | | Current assets | $m | [42.4](/filings/0000950170-25-041974.md) | [42.6](/filings/0000950170-24-056865.md) | [41.8](/filings/0000950170-24-093868.md) | [38.2](/filings/0000950170-24-121839.md) | [32.2](/filings/0001193125-26-114051.md) | [32.6](/filings/0000950170-25-065032.md) | [32.4](/filings/0000950170-25-104624.md) | [36.0](/filings/0001193125-25-265826.md) | [50.8](/filings/0001193125-26-435152.md) | [49.4](/filings/0001193125-26-207665.md) | [54.2](/filings/0001193125-26-333905.md) | [45.9](/filings/0001193125-26-435152.md) | | Total assets | $m | [48.3](/filings/0000950170-25-041974.md) | [48.3](/filings/0000950170-24-056865.md) | [47.4](/filings/0000950170-24-093868.md) | [43.7](/filings/0000950170-24-121839.md) | [36.9](/filings/0001193125-26-114051.md) | [37.1](/filings/0000950170-25-065032.md) | [39.4](/filings/0000950170-25-104624.md) | [43.1](/filings/0001193125-25-265826.md) | [52.8](/filings/0001193125-26-435152.md) | [51.2](/filings/0001193125-26-207665.md) | [55.8](/filings/0001193125-26-333905.md) | [47.4](/filings/0001193125-26-435152.md) | | Current liabilities | $m | [6.9](/filings/0000950170-25-041974.md) | [8.2](/filings/0000950170-24-056865.md) | [9.2](/filings/0000950170-24-093868.md) | [11.5](/filings/0000950170-24-121839.md) | [8.2](/filings/0001193125-26-114051.md) | [9.6](/filings/0000950170-25-065032.md) | [9.2](/filings/0000950170-25-104624.md) | [12.9](/filings/0001193125-25-265826.md) | [5.6](/filings/0001193125-26-435152.md) | [4.6](/filings/0001193125-26-207665.md) | [16.1](/filings/0001193125-26-333905.md) | [8.1](/filings/0001193125-26-435152.md) | | Total liabilities | $m | [8.7](/filings/0000950170-25-041974.md) | [9.9](/filings/0000950170-24-056865.md) | [10.9](/filings/0000950170-24-093868.md) | [13.0](/filings/0000950170-24-121839.md) | [9.8](/filings/0001193125-26-114051.md) | [11.1](/filings/0000950170-25-065032.md) | [13.2](/filings/0000950170-25-104624.md) | [16.7](/filings/0001193125-25-265826.md) | [6.8](/filings/0001193125-26-435152.md) | [5.8](/filings/0001193125-26-207665.md) | [17.2](/filings/0001193125-26-333905.md) | [9.1](/filings/0001193125-26-435152.md) | | Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [2.2](/filings/0001193125-25-265826.md) | not reported | not reported | not reported | not reported | | Shareholders' equity | $m | [39.6](/filings/0001193125-26-114051.md) | [38.4](/filings/0000950170-25-104624.md) | [36.5](/filings/0001193125-25-265826.md) | [30.6](/filings/0001193125-25-265826.md) | [27.2](/filings/0001193125-26-435152.md) | [26.0](/filings/0001193125-26-333905.md) | [26.2](/filings/0001193125-26-435152.md) | [26.3](/filings/0001193125-26-435152.md) | [46.0](/filings/0001193125-26-435152.md) | [45.3](/filings/0001193125-26-333905.md) | [38.6](/filings/0001193125-26-435152.md) | [38.3](/filings/0001193125-26-435152.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: not reported - Current portion of debt: us-gaap:LongTermDebtCurrent - Shareholders' equity: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest ## Cash flow | Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [(0.7) d](/filings/0000950170-25-041974.md) | [2.0](/filings/0000950170-25-065032.md) | [(0.8) d](/filings/0000950170-25-104624.md) | [0.9 d](/filings/0001193125-25-265826.md) | [(2.3) d](/filings/0000950170-25-041974.md) | [(1.1)](/filings/0000950170-25-065032.md) | [(0.4) d](/filings/0000950170-25-104624.md) | [(3.4) d](/filings/0001193125-25-265826.md) | [(1.6) d](/filings/0001193125-26-114051.md) | [4.0](/filings/0001193125-26-207665.md) | [(4.7) d](/filings/0001193125-26-333905.md) | [(11.8) d](/filings/0001193125-26-435152.md) | | Capital expenditure | $m | [0.4 d](/filings/0000950170-25-041974.md) | [0.2](/filings/0000950170-25-065032.md) | [0.0 d](/filings/0000950170-25-104624.md) | [0.1 d](/filings/0001193125-25-265826.md) | [(0.1) d](/filings/0001193125-26-114051.md) | [0.0](/filings/0001193125-26-207665.md) | [0.0 d](/filings/0001193125-26-333905.md) | [0.1 d](/filings/0001193125-26-435152.md) | [0.0 d](/filings/0001193125-26-114051.md) | [0.0](/filings/0001193125-26-207665.md) | [0.1 d](/filings/0001193125-26-333905.md) | [0.1 d](/filings/0001193125-26-435152.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities, us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment ## Shares | Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [20.3](/filings/0000950170-24-056865.md) | [20.4](/filings/0000950170-24-093868.md) | [20.6](/filings/0000950170-24-121839.md) | [20.7](/filings/0000950170-25-065032.md) | [20.9](/filings/0000950170-25-104624.md) | [21.0](/filings/0001193125-25-265826.md) | [22.0](/filings/0001193125-26-333905.md) | [22.0](/filings/0001193125-26-333905.md) | [22.8](/filings/0001193125-26-435152.md) | [24.7](/filings/0001193125-26-207665.md) | [24.8](/filings/0001193125-26-333905.md) | [25.0](/filings/0001193125-26-435152.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 25,037,445 at 2026-10-23, from the cover of the [10-Q filed 2026-10-28](/filings/0001193125-26-435152.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 28, 2026, 08:32 ET. No prices; not investment advice.